Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
01 avr. 2024 16h01 HE
|
Compass Pathways
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
28 mars 2024 08h00 HE
|
Compass Pathways
LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
29 févr. 2024 07h00 HE
|
Compass Pathways
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line...
Compass Pathways to participate in upcoming TD Cowen investor conference
26 févr. 2024 16h01 HE
|
Compass Pathways
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
22 févr. 2024 16h01 HE
|
Compass Pathways
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways to participate in upcoming Oppenheimer investor conference
31 janv. 2024 16h01 HE
|
Compass Pathways
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
16 janv. 2024 08h00 HE
|
Compass Pathways; Hackensack Meridian Health
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
05 janv. 2024 08h00 HE
|
Compass Pathways; Greenbrook TMS
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
19 déc. 2023 16h05 HE
|
Compass Pathways
LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways appoints Teri Loxam as Chief Financial Officer
07 déc. 2023 07h00 HE
|
Compass Pathways
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...